Synthesis and in vitro biological evaluation of thiosulfinate derivatives for the treatment of human multidrug-resistant breast cancer

• 来源期刊: 中国药理学报（英文版）
• 关键词: garlic allicin thiosulfinate derivatives breast cancer multidrug resistance cell cycle arrest apoptosis mitochondrial respiration
• 年，卷（期）: 2017,（10）
• 页码范围: 1353-1368
• 页数: 16页
• 语种: 英文
• DOI: 10.1038/aps.2016.170

摘要

Organosulfur compounds derived from Allium vegetables have long been recognized for various therapeutic effects,including anticancer activity.Allicin,one of the main biologically active components of garlic,shows promise as an anticancer agent;however,instability makes it unsuitable for clinical application.The aim of this study was to investigate the effect of stabilized allicin derivatives on human breast cancer cells in vitro.In this study,a total of 22 stabilized thiosulfinate derivatives were synthesized and screened for their in vitro antiproliferative activities against drug-sensitive (MCF-7) and multidrug-resistant (MCF-7/Dx) human adenocarcinoma breast cancer cells.Assays for cell death,apoptosis,cell cycle progression and mitochondrial bioenergetic function were performed.Seven compounds (4b,7b,8b,13b,14b,15b and 18b) showed greater antiproliferative activity against MCF-7/Dx cells than allicin.These compounds were also selective towards multidrug-resistant (MDR) cells,a consequence attributed to collateral sensitivity.Among them,13b exhibited the greatest anticancer activity in both MCF-7/Dx and MCF-7 cells,with IC5o values of 18.54±0.24 and 46.50±1.98 μmol/L,respectively.13b altered cellular morphology and arrested the cell cycle at the G2/M phase.Additionally,13b dose-dependently induced apoptosis,and inhibited cellular mitochondrial respiration in cells at rest and under stress.MDR presents a significant obstacle to the successful treatment of cancer clinically.These results demonstrate that thiosulfinate derivatives have potential as novel anticancer agents and may offer new therapeutic strategies for the treatment of chemoresistant cancers.